The combined treatment with a specific CXCR4 antagonist, AMD3100, and an AKT inhibitor, GSK690693, synergistically impeded the progression of GBM cells, suggesting novel potential therapeutic strategies for this cancer. This evidence concerns the gene AKT1 and cancer.